Clinical Trial Update: A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of Moderna's RSV vaccine mRNA-1345 in children aged 2 to under 18 at high risk has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• mRNA-1345

Snippet

Sponsor: ModernaTX, Inc. | Conditions: Respiratory Syncytial Virus | Phase 2 | Status: COMPLETED